Publication | Closed Access
Bioavailability ofL-DOPA from HP-200—a Formulation of Seed Powder ofMucuna pruriens(Bak): a Pharmacokinetic and Pharmacodynamic Study
22
Citations
0
References
1996
Year
Pharmaceutical SciencePharmacotherapyHplc TechniqueMolecular PharmacologyPharmacodynamic StudyBioanalysisClinical ChemistrySynthetic L-dopaTherapeutic Drug MonitoringNeuropharmacologyHp-200—a FormulationPharmacologyHerbal MedicinePhysiologyHerb-drug InteractionBioavailability Ofl-dopaClinical PharmacologySeed PowderMedicinePharmacokineticsDrug Analysis
HP-200, a formulation made from the seed powder of Mucuna pruriens, contains among other constituents, about 4% L-DOPA. After five normal human volunteers were each given a single oral dose of 30 g of HP-200, plasma samples were obtained at 0, 20, 40, 60, 90, 120, 180, 240 and 360 min for assay of L-DOPA by HPLC technique using electrochemical detection. The supine systolic and diastolic blood pressures were recorded at each sampling time. The results indicate that on oral administration, L-DOPA was absorbed from HP-200 with plasma peak levels (Cmax=1.56±0.163 μg/mL) achieved at Tmax=83±16.09 min. The plasma half life was 102±2 min and the auc was determined as 6.508±0.421 μg/h/mL. The pharmacokinetic profile of HP-200 exhibited characteristics similar to formulations of synthetic L-DOPA, except for the lack of a sharp peak. HP-200, a new herbal formulation, appears to be suitable for the treatment of Parkinson's disease.